

September 16, 2013



## **DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com**

**Company invites individual and institutional investors to log-on to view presentation**

NEW YORK, Sept. 16, 2013 /PRNewswire/ -- [DelMar Pharmaceuticals, Inc.](#) (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that their September 12th RetailInvestorConferences.com presentation is now available for on-demand viewing. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers.

DelMar's lead drug, VAL-083, is being developed in the U.S. to treat glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 is approved in China to treat chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and in the United States.

### **On-demand Viewing of DelMar's Investor Presentation**

DelMar Pharmaceuticals, Inc.'s presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

LINK: [www.retailinvestorconferences.com](http://www.retailinvestorconferences.com) > click on the red "register/ watch event now" button

### **DelMar Pharmaceuticals Recent 2013 Highlights**

- **September:** DelMar establishes clinical advisory board to oversee new clinical studies in China
- **August:** FDA Allows Accelerated Dose-escalation for VAL-083 Clinical Trial in Glioblastoma
- **July:** VAL-083 Clinical Trial in Glioblastoma Expands to UC San Francisco (UCSF)
- **July:** DelMar and Guangxi Wuzhou Announce Chinese Government Funding Award
- **July:** First U.S. Patent Issued for VAL-083, Part of International IP Strategy
- **June:** Presented additional supportive data from ongoing Phase I/II glioblastoma multiforme (GBM) clinical trial with VAL-083 at the American Society of Clinical Oncology (ASCO) Annual Meeting

**DelMar Is Developing Essential New Treatments For Aggressive Brain Cancers**

Fifty percent of patients with GBM will fail today's approved therapies, Temodar<sup>®</sup> and Avastin<sup>®</sup>. Tumor resistance to Temodar is well documented and known to be caused by the MGMT enzyme. Studies by the National Cancer Institute and DelMar have shown that VAL-083 acts through a unique mechanism unaffected by MGMT and has activity against a range of cancers.

DelMar is conducting a Phase I/II clinical trial to assess the safety and efficacy of VAL-083 as a potential new treatment for GBM patients who have failed standard therapies. In June, DelMar reported encouraging interim results from the trial at the American Society for Clinical Oncology (ASCO). Last month, the FDA allowed DelMar to accelerate the dose-escalation in the clinical trial.

Temodar generates more than US\$950 million annually in global revenues, primarily from the treatment of brain cancer.

In addition to its clinical activities in the United States, DelMar has acquired the commercial rights to VAL-083 in China, where it is approved for chronic myelogenous leukemia (CML) and lung cancer. DelMar and its manufacturing partner, Guangxi Wuzhou Pharmaceuticals, plan to work with leading clinicians in China to develop new post-market data to support the sales and marketing of VAL-083 in these indications in China and to expand the market opportunities for the drug on a worldwide basis.

### **About DelMar Pharmaceuticals**

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

### **About RetailInvestorConferences.com:**

Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

### **Safe Harbor Statement**

*Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based*

*on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.*

SOURCE DelMar Pharmaceuticals, Inc.